MicroRNA in the pathogenesis and prognosis of esophageal cancer

Current Pharmaceutical Design

Volumn 19, Issue 7, 2013, Pages 1292-1300

  Gu, Jian ^a   Wang, Yan ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Barrett's esophagus; Circulating biomarker; Early detection; Esophageal cancer; MicroRNA; Prognosis

Indexed keywords

ALPHA TROPOMYOSIN; BIM PROTEIN; BIOLOGICAL MARKER; CALGRANULIN B; FASCIN; FASCIN 1; KRUPPEL LIKE FACTOR 4; LET 7C PROTEIN; MEMBRANE RECEPTOR; MICRORNA; MICRORNA 100; MICRORNA 125B; MICRORNA 192; MICRORNA 194; MICRORNA 200A; MICRORNA 200C; MICRORNA 203; MICRORNA 205; MICRORNA 21; MICRORNA 27B; MICRORNA 31; MICRORNA 375; MICRORNA 93; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROGRAMMED CELL DEATH 4; PROTEIN P21; SMALL UNTRANSLATED RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CANCER TISSUE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DISEASE SEVERITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS DYSPLASIA; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SCREENING TEST;

EID: 84876698299     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804805775     Document Type: Article

References (113)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
2. Howlader N NA, Krapcho M, Neyman N, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD,. http: //seercancergov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
3. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009; 24(5): 729-35.
4. Pera M. Recent changes in the epidemiology of esophageal cancer. Surgical Oncology-Oxford 2001; 10(3): 81-90.
5. Lee RC, Feinbaum RL, Ambros V. The C-Elegans Heterochronic Gene Lin-4 Encodes Small RNas with Antisense Complementarity to Lin-14 Cell 1993; 75(5): 843-54.
6. Wheeler BM, Heimberg AM, Moy VN, et al. The deep evolution of metazoan microRNAs. Evolution Development 2009; 11(1): 50-68.
7. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6(11): 857-66.
8. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433(7027): 769-73.
9. Friedman RC, Farh KKH, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19(1): 92-105.
10. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120(1): 15-20.
11. Calin GA, Sevignani C, Dan Dumitru C, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Nat Acad Sci USA 2004; 101(9): 2999-3004.
12. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. In: Annual Review of Medicine. 60. 2009; 167-79.
13. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435(7043): 834-8.
14. Kan T, Meltzer SJ. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol 2009; 9(6): 727-32.
15. Smith CM, Watson DI, Michael MZ, Hussey DJ. MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol 2010; 16(5): 531-7.
16. Zhou SL, Wang LD. Circulating microRNAs: novel biomarkers for esophageal cancer. World J Gastroenterol 2010; 16(19): 2348-54.
17. Matsushima K, Isomoto H, Kohno S, Nakao K. MicroRNAs and esophageal squamous cell carcinoma. Digestion 2010; 82(3): 138-44.
18. David S, Meltzer SJ. MicroRNA involvement in esophageal carcinogenesis. Curr Opin Pharmacol 2011; 11(6): 612-6.
19. Ichikawa D, Komatsu S, Konishi H, Otsuji E. Circulating microRNA in digestive tract cancers. Gastroenterology 2012; 142(5): 1074-1078 e1071.
20. Song JH, Meltzer SJ. MicroRNAs in Pathogenesis, Diagnosis, and Treatment of Gastroesophageal Cancers. Gastroenterology 2012; 143(1): 35-47 e32.
21. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120(7): 1607-19.
22. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet 2009; 373(9666): 850-61.
23. Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thoracic Cardiovascular Surgery 2008; 135(2): 255-60.
24. Yang H, Gu J, Wang KK, et al. MicroRNA Expression Signatures in Barrett's Esophagus and Esophageal Adenocarcinoma. Clinical Cancer Res 2009; 15(18): 5744-52.
25. Kan T, Sato F, Ito T, et al. The miR-106b-25 Polycistron, Activated by Genomic Amplification, Functions as an Oncogene by Suppressing p21 and Bim. Gastroenterol 2009; 136(5): 1689-700.
26. Wijnhoven BPL, Hussey DJ, Watson DI, et al. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surgery 2010; 97(6): 853-61.
27. Mathe EA, Nguyen GH, Bowman ED, et al. MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival. Clinical Cancer Res 2009; 15(19): 6192-200.
28. Fassan M, Volinia S, Palatini J, et al. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer 129(7): 1661-70.
29. Dijckmeester WA, Wijnhoven BPL, Watson DI, et al. MicroRNA-143 and-205 Expression in Neosquamous Esophageal Epithelium Following Argon Plasma Ablation of Barrett's Esophagus. J Gastrointestinal Surgery 2009; 13(5): 846-53.
30. Luthra R, Singh RR, Luthra MG, et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 2008; 27(52): 6667-78.
31. Maru DM, Singh RR, Hannah C, et al. MicroRNA-196a Is a Potential Marker of Progression during Barrett's Metaplasia-Dysplasia-Invasive Adenocarcinoma Sequence in Esophagus. Am J Pathol 2009; 174(5): 1940-8.
32. Guo Y, Chen Z, Zhang L, et al. Distinctive MicroRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008; 68(1): 26-33.
33. Lee KH, Goan YG, Hsiao M, et al. MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Experimental Cell Res 2009; 315(15): 2529-38.
34. Ogawa R, Ishiguro H, Kuwabara Y, et al. Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Medical Molecular Morphology 2009; 42(2): 102-9.
35. Kano M, Seki N, Kikkawa N, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. International J Cancer 2010; 127(12): 2804-14.
36. Kimura S, Naganuma S, Susuki D, et al. Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Reports 2010; 23(6): 1625-33.
37. Hong L, Han Y, Zhang H, et al. The Prognostic and Chemotherapeutic Value of miR-296 in Esophageal Squamous Cell Carcinoma. Annals Surgery 2010; 251(6): 1056-63.
38. Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H, Liu Z. MicroRNA-10b Promotes Migration and Invasion through KLF4 in Human Esophageal Cancer Cell Lines. J Biol Chem 2010; 285(11): 7986-94.
39. Liu M, Wang Z, Yang S, et al. TNF-alpha is a novel target of miR-19a. Int J Oncol 2011; 38(4): 1013-22.
40. Zhang TF, Wang QM, Zhao D, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci 2011; 121(9-10): 437-47.
41. Ding DP, Chen ZL, Zhao XH, et al. miR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression. Carcinogenesis 2011; 32(7): 1025-32.
42. Tsuchiya S, Fujiwara T, Sato F, et al. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem 2011; 286(1): 420-8.
43. Akagi I, Miyashita M, Ishibashi O, et al. Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Diseases Esophagus 2011; 24(7): 523-30.
44. Hummel R, Hussey DJ, Michael MZ, et al. MiRNAs and Their Association with Locoregional Staging and Survival Following Surgery for Esophageal Carcinoma. Annals Surgical Oncol 2011; 18(1): 253-60.
45. Kong KL, Kwong DL, Chan TH, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012; 61(1): 33-42.
46. Nguyen GH, Schetter AJ, Chou DB, et al. Inflammatory and MicroRNA Gene Expression as Prognostic Classifier of Barrett's-Associated Esophageal Adenocarcinoma. Clinical Cancer Res 2010; 16(23): 5824-34.
47. Chen Zl, Zhao XH, Wang JW, et al. microRNA-92a Promotes Lymph Node Metastasis of Human Esophageal Squamous Cell Carcinoma via E-Cadherin. J Biol Chem 2011; 286(12): 10725-10734.
48. Kurashige J, Watanabe M, Iwatsuki M, et al. Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer 2012; 106(1): 182-188.
49. Lin RJ, Xiao DW, Liao LD, et al. MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma. J Surgical Oncol 2012; 105(2): 175-82.
50. Suzuki S, Yokobori T, Tanaka N, et al. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Reports 2012; (In press)
51. Hu Y, Correa AM, Hoque A, et al. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 2011; 128(1): 132-43.
52. Feber A, Xi L, Pennathur A, et al. MicroRNA Prognostic Signature for Nodal Metastases and Survival in Esophageal Adenocarcinoma. Annals Thoracic Surgery 2011; 91(5): 1523-30.
53. Selcuklu SD, Donoghue MTA, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochemical Society Transactions 2009; 37: 918-25.
54. Hiyoshi Y, Kamohara H, Karashima R, et al. MicroRNA-21 Regulates the Proliferation and Invasion in Esophageal Squamous Cell Carcinoma. Clinical Cancer Res 2009; 15(6): 1915-22.
55. Xu X, Chen Z, Zhao X, et al. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 2012; 421(4): 640-5.
56. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435(7043): 828-33.
57. Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010; 42(8): 1348-54.
58. Chen ZL, Zhao XH, Wang JW, et al. microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem 2011; 286(12): 10725-34.
59. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47(6): 1955-63.
60. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 2010; 12(2).
61. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 2009; 125(6): 1407-13.
62. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc NatAcad Sci USA 2008; 105(10): 3945-50.
63. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA 10b in breast cancer. Nature 2007; 449(7163): 682-2.
64. Yoon HS, Chen XM, Yang VW. Kruppel-like factor 4 mediates p53-dependent G(1)/S cell cycle arrest in response to DNA damage. J Biol Chem 2003; 278(4): 2101-5.
65. Schimanski CC, Frerichs K, Rahman F, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 2009; 15(17): 2089-96.
66. Zhang Y, Li M, Wang H, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg 2009; 33(4): 698-709.
67. Hui AB, Shi W, Boutros PC, et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 2009; 89(5): 597-606.
68. Paweletz CP, Ornstein DK, Roth MJ, et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 2000; 60(22): 6293-7.
69. Xia SH, Hu LP, Hu H, et al. Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but downregulated in esophageal squamous cell carcinomas. Oncogene 2002; 21(43): 6641-8.
70. Hu N, Flaig MJ, Su H, et al. Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. Clin Cancer Res 2004; 10(18 Pt 1): 6013-22.
71. Li X, Lin R, Li J. Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer. Dig Dis Sci 2011; 56(10): 2849-56.
72. Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219(2): 214-21.
73. Childs G, Fazzari M, Kung G, et al. Low-Level Expression of MicroRNAs let-7d and miR-205 Are Prognostic Markers of Head and Neck Squamous Cell Carcinoma. Am J Pathol 2009; 174(3): 736-45.
74. Gandellini P, Folini M, Longoni N, et al. miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase C epsilon. Cancer Res 2009; 69(6): 2287-95.
75. Wu H, Mo YY. Targeting miR-205 in breast cancer. Expert Opinion on Therapeutic Targets 2009; 13(12): 1439-48.
76. Matsushima K, Isomoto H, Yamaguchi N, et al. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med 2011; 9(30.
77. Sachdeva M, Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. American J translational Res 2010; 2(2): 170-80.
78. Michael MZ, O'Connor SM, Pellekaan NGV, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1(12): 882-91.
79. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered microRNA expression confined to specific epithelial cell Subpopulations in breast cancer. Cancer Res 2007; 67(24): 11612-20.
80. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-145 Targets YES and STAT1 in Colon Cancer Cells. PLoS One 2010; 5(1).
81. Ostenfeld MS, Bramsen JB, Lamy P, et al. miR-145 induces caspase-dependent and-independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 2010; 29(7): 1073-84.
82. Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Nat Acad Sci USA 2009; 106(9): 3207-12.
83. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency in Human Embryonic Stem Cells. Cell 2009; 137(4): 647-58.
84. Hashimoto Y, Ito T, Inoue H, et al. Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11(7): 2597-2605.
85. Yuan Y, Zeng ZY, Liu XH, et al. MicroRNA-203 inhibits cell proliferation by repressing DeltaNp63 expression in human esophageal squamous cell carcinoma. BMC Cancer 2011; 11(57.
86. Mitchell P, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
87. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141(5): 672-5.
88. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer. Annals of Surgery 2010; 251(3): 499-505.
89. Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2009; 2: 89-93.
90. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. International J Cancer 2010; 127: 118-26.
91. Ng E, Chong W, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-81.
92. Liu HS, Zhu L, Liu BY, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 2012; 316(2): 196-203.
93. Liu R, Zhang CN, Hu ZB, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011; 47(5): 784-91.
94. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102(7): 1174-9.
95. Chen X, Ba Y, Ma LJ, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18(10): 997-1006.
96. Rosell R, Wei J, Taron M. Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer. Clin Lung Cancer 2009; 10(1): 8-9.
97. Hu ZB, Chen X, Zhao Y, et al. Serum MicroRNA Signatures Identified in a Genome-Wide Serum MicroRNA Expression Profiling Predict Survival of Non-Small-Cell Lung Cancer. J Clin Oncol 2010; 28(10): 1721-6.
98. Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW, Lin SC. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis 2010; 16(4): 360-4.
99. Qin YR, Fu L, Sham PC, et al. Single-nucleotide polymorphismmass array reveals commonly deleted regions at 3p22 and 3p14.2 associate with poor clinical outcome in esophageal squamous cell carcinoma. International J Cancer 2008; 123(4): 826-30.
100. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009; 112(1): 55-9.
101. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110(1): 13-21.
102. Ho AS, Huang X, Cao HB, et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol 2010; 3(2): 109-13.
103. Wang J, Chen JY, Chang P, et al. MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease. Cancer Prevention Res 2009; 2(9): 807-813.
104. Zhang CN, Wang C, Chen X, et al. Expression Profile of MicroRNAs in Serum: A Fingerprint for Esophageal Squamous Cell Carcinoma. Clin Chem 2010; 56(12): 1871-9.
105. Zhang T, Zhao D, Wang Q, et al. MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma. Mol Carcinogenesis 2012; (In press)
106. Komatsu S, Ichikawa D, Takeshita H, et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011; 105(1): 104-111.
107. Komatsu S, Ichikawa D, Takeshita H, et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert opinion Biol Therapy 2012; 12(S1): S53-59.
108. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10(6): 389-402.
109. Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 2008; 29(7): 1306-11.
110. Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA Complementary Site in the KRAS 3 ' Untranslated Region Increases Non-Small Cell Lung Cancer Risk. Cancer Res 2008; 68(20): 8535-40.
111. Guo H, Wang K, Xiong G, et al. A functional varient in microRNA-146a is associated with risk of esophageal squamous cell carcinoma in Chinese Han. Fam Cancer 2010; 9(4): 599-603.
112. Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, Wu X. Genetic Variations in MicroRNA-Related Genes Are Novel Susceptibility Loci for Esophageal Cancer Risk. Cancer Prevention Res 2008; 1(6): 460-9.
113. Hamano R, Miyata H, Yamasaki M, et al. Overexpression of miR-200c Induces Chemoresistance in Esophageal Cancers Mediated Through Activation of the Akt Signaling Pathway. Clinical Cancer Res 2011; 17(9): 3029-38.